Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: A case report

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 6, 2014, Pages 691-694

  Kong, H ^a   Wang, Y ^a   Zeng, X ^a   Zhu, Q ^a   Xie, W ^a   Dai, Shanlin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Inflammasome; Interstitial lung disease; Rituximab

Indexed keywords

CD19 ANTIGEN; CEFOXITIN; CILASTATIN PLUS IMIPENEM; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROCALCITONIN; RITUXIMAB; CARRIER PROTEIN; CYTOKINE; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NLRP3 PROTEIN, HUMAN;

ADULT; ANTIBIOTIC THERAPY; APOPTOSIS; ARTICLE; BREATHING RATE; CASE REPORT; CELL INFILTRATION; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRACKLE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPNEA; FEVER; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPOXEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOCOMPROMISED PATIENT; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; LUNG BIOPSY; LUNG INFILTRATE; LUNG INTERSTITIUM; MALE; MULTIPLE CYCLE TREATMENT; OXYGEN SATURATION; OXYGEN TENSION; PNEUMONIA; PROTEIN EXPRESSION; PULSE RATE; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; STEROID THERAPY; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY; BLOOD; CHEMICALLY INDUCED; INTERSTITIAL LUNG DISEASE; METABOLISM; PATHOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CARRIER PROTEINS; CYTOKINES; DYSPNEA; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMASOMES; LUNG DISEASES, INTERSTITIAL; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84912095125     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12198     Document Type: Article

References (15)

1. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol, 2008;141:149-169.
2. Liote H, Liote F, Seroussi B et al. Rituximabinduced lung disease: a systematic literature review. Eur Respir J, 2010;35:681-687.
3. Zaja F, Battista ML, Pirrotta MT et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica, 2008;93:930-933.
4. Hadjinicolaou AV, Nisar MK, Parfrey H et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford), 2012;51:653-662.
5. O'Connor MB, Abdullah MF, O'Donovan N et al. Rituximab-induced pulmonary disease. Rheumatol Int, 2012;32:2955-2956.
6. Zayen A, Rais H, Rifi H et al. Rituximabinduced interstitial lung disease: case report and literature review. Pharmacology, 2011;87:318-320.
7. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant, 2011;11:1359-1367.
8. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol, 2013;13:397-411.
9. Kersse K, Bertrand MJ, Lamkanfi M et al. NOD-like receptors and the innate immune system: coping with danger, damage and death. Cytokine Growth Factor Rev, 2011;22:257-276.
10. Schroder K, Tschopp J. The inflammasomes. Cell, 2010;140:821-832.
11. Aumiller V, Balsara N, Wilhelm J et al. WNT/beta-catenin signaling induces IL-1beta expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol, 2013;49:96-104.
12. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med, 2011;208:1339-1350.
13. Guo J, Gu N, Chen J et al. Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice. Arch Toxicol, 2013;87:1963-1973.
14. Kawayama T, Okamoto M, Imaoka H et al. Interleukin-18 in pulmonary inflammatory diseases. J Interferon Cytokine Res, 2012;32:443-449.
15. Segawa S, Goto D, Yoshiga Y et al. Inhibition of transforming growth factor-beta signalling attenuates interleukin (IL)-18 plus IL-2-induced interstitial lung disease in mice. Clin Exp Immunol, 2010;160:394-402.